BDTX Black Diamond Therapeutics, Inc. Stock Quote

BDTX [NASD]

Index	-	P/E	-	EPS (ttm)	-1.72	Insider Own	2.10%	Shs Outstand	35.93M	Perf Week	-10.36%
Market Cap	854.15M	Forward P/E	-	EPS next Y	-2.51	Insider Trans	-52.26%	Shs Float	34.84M	Perf Month	-7.45%
Income	-54.50M	PEG	-	EPS next Q	-0.63	Inst Own	86.09%	Short Float	10.10%	Perf Quarter	-23.08%
Sales	-	P/S	-	EPS this Y	-294.80%	Inst Trans	8.72%	Short Ratio	7.65	Perf Half Y	-16.39%
Book/sh	9.11	P/B	2.76	EPS next Y	-20.70%	ROA	-17.90%	Target Price	-	Perf Year	-21.98%
Cash/sh	9.79	P/C	2.56	EPS next 5Y	-	ROE	-22.30%	52W Range	17.63 - 46.25	Perf YTD	-21.68%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-45.73%	Beta	-
Dividend %	-	Quick Ratio	29.70	Sales past 5Y	-	Gross Margin	-	52W Low	42.37%	ATR	1.78
Employees	32	Current Ratio	29.70	Sales Q/Q	-	Oper. Margin	-	RSI (14)	39.10	Volatility	8.40% 6.44%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-75.60%	Profit Margin	-	Rel Volume	1.28	Prev Close	23.73
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	460.08K	Price	25.10
Recom	1.60	SMA20	-9.47%	SMA50	-12.77%	SMA200	-21.75%	Volume	586,968	Change	5.77%

Jan-07-21

Initiated

Wedbush

Outperform

$45

Nov-24-20

Initiated

Berenberg

Buy

$58

May-04-20

Initiated

H.C. Wainwright

Buy

$53

Feb-24-20

Initiated

JP Morgan

Overweight

$42

Feb-24-20

Initiated

Jefferies

Buy

Feb-24-20

Initiated

Cowen

Outperform

Feb-24-20

Initiated

Canaccord Genuity

Buy

$50

Mar-02-21 04:05PM	Black Diamond Therapeutics Announces Pre-Clinical Data Presentations on New Programs Targeting BRAF and FGFR at ESMO TAT Virtual Congress 2021 GlobeNewswire
Feb-23-21 07:45AM	Black Diamond Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Feb-11-21 04:15PM	Black Diamond Therapeutics to Present at the BMO Biopharma Spotlight Series GlobeNewswire
Feb-02-21 11:51PM	We Think Black Diamond Therapeutics (NASDAQ:BDTX) Can Afford To Drive Business Growth Simply Wall St.
07:32PM	2 Biotech Stocks That Could Double in 2021; Canaccord Says Buy TipRanks
Jan-20-21 07:45AM	Black Diamond Therapeutics Announces Appointment of Oncology Clinical Development Veteran Dr. Kapil Dhingra to Board of Directors GlobeNewswire
Jan-05-21 07:45AM	Black Diamond Therapeutics to Present at the J.P. Morgan 39th Annual Healthcare Conference GlobeNewswire
Dec-14-20 12:51PM	Is BDTX A Good Stock To Buy Now? Insider Monkey
Dec-05-20 01:55AM	What Kind Of Shareholders Own Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)? Simply Wall St.
Nov-24-20 07:45AM	Black Diamond Therapeutics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference GlobeNewswire
Nov-20-20 07:45AM	Black Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meeting GlobeNewswire
Nov-11-20 07:45AM	Black Diamond Therapeutics to Present at the Jefferies 2020 Virtual London Healthcare Conference GlobeNewswire
Nov-10-20 07:45AM	Black Diamond Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire +6.08%
Oct-26-20 07:45AM	Black Diamond Therapeutics Presents Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium GlobeNewswire
Oct-12-20 07:45AM	Black Diamond Therapeutics to Present Pre-Clinical Data on Lead Product Candidate BDTX-189 at the 32nd EORTC-NCI-AACR Virtual Symposium GlobeNewswire
Oct-03-20 08:00AM	Insider Buying: Robert Ingram Just Spent US$152k On Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Shares Simply Wall St.
Sep-29-20 07:45AM	Black Diamond Therapeutics Announces the Appointment of Biopharmaceutical Veteran Robert A. Ingram as Chairman of the Board GlobeNewswire +5.96%
Sep-10-20 07:45AM	Black Diamond Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference GlobeNewswire
Sep-08-20 04:05PM	Black Diamond Therapeutics Announces the Appointment of Rachel Humphrey, M.D., as Chief Medical Officer GlobeNewswire
Aug-11-20 07:45AM	Black Diamond Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Aug-10-20 08:42AM	Is a Surprise Coming for Black Diamond Therapeutics (BDTX) This Earnings Season? Zacks +8.76%
Aug-05-20 07:45AM	Black Diamond Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Aug-04-20 07:45AM	Black Diamond Therapeutics Announces the Appointment of Fang Ni as Chief Business Officer GlobeNewswire
Jul-30-20 09:58AM	We're Not Very Worried About Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Rate Simply Wall St.
Jul-28-20 07:45AM	Black Diamond Therapeutics Granted Fast Track Designation by the FDA for BDTX-189 for the Treatment of Adult Patients with a Solid Tumor Harboring an Allosteric HER2 Mutation or an EGFR or HER2 Exon 20 Insertion Mutation GlobeNewswire
Jun-16-20 07:45AM	Black Diamond Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference GlobeNewswire
May-27-20 07:45AM	Black Diamond Therapeutics to Present at the Jefferies Virtual Healthcare Conference GlobeNewswire
May-13-20 05:15PM	Black Diamond Therapeutics Announces Accepted Abstract for Lead Product Candidate BDTX-189 at American Society of Clinical Oncology 2020 GlobeNewswire
May-12-20 07:45AM	Black Diamond Therapeutics Reports First Quarter 2020 Financial Results and Corporate Update GlobeNewswire
May-06-20 07:45AM	Black Diamond Therapeutics to Present at the Bank of America Global Research Health Care Conference 2020 GlobeNewswire
May-05-20 11:46AM	3 Biotech Stocks With Plenty of Upside in the Pipeline TipRanks
Feb-24-20 09:37AM	Black Diamonds Cancer Drug May Be a Master Key, Street Says Bloomberg -12.26%
Jan-30-20 04:29PM	Black Diamond Therapeutics Doubles After $201 Million IPO Bloomberg

Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Roberts Christopher D.	Chief Scientific Officer	Mar 03	Option Exercise	10.86	2,500	27,150	5,700	Mar 04 05:52 PM
Roberts Christopher D.	Chief Scientific Officer	Mar 03	Sale	26.10	2,500	65,262	3,200	Mar 04 05:52 PM
Hatzis-Schoch Brent	See Remarks	Feb 12	Option Exercise	3.20	4,078	13,050	12,478	Feb 12 09:24 PM
Hatzis-Schoch Brent	See Remarks	Feb 12	Sale	27.23	4,078	111,025	8,400	Feb 12 09:24 PM
Roberts Christopher D.	Chief Scientific Officer	Feb 03	Option Exercise	10.86	2,500	27,150	5,700	Feb 04 05:47 PM
Roberts Christopher D.	Chief Scientific Officer	Feb 03	Sale	25.35	2,500	63,375	3,200	Feb 04 05:47 PM
Hatzis-Schoch Brent	See Remarks	Jan 12	Option Exercise	8.16	11,578	94,500	19,978	Jan 14 08:57 PM
Hatzis-Schoch Brent	See Remarks	Jan 12	Sale	34.03	11,578	394,041	8,400	Jan 14 08:57 PM
Leggett Thomas	Chief Financial Officer	Jan 08	Option Exercise	10.86	3,000	32,580	3,000	Jan 11 05:59 PM
Leggett Thomas	Chief Financial Officer	Jan 08	Sale	33.94	3,000	101,820	0	Jan 11 05:59 PM
Epstein David M.	See Remarks	Jan 04	Option Exercise	6.42	3,000	19,260	708,423	Jan 06 06:21 PM
Roberts Christopher D.	Chief Scientific Officer	Jan 04	Option Exercise	10.86	2,500	27,150	5,700	Jan 06 06:27 PM
Epstein David M.	See Remarks	Jan 04	Sale	31.13	12,000	373,505	696,423	Jan 06 06:21 PM
Roberts Christopher D.	Chief Scientific Officer	Jan 04	Sale	31.41	2,500	78,525	3,200	Jan 06 06:27 PM
Hatzis-Schoch Brent	See Remarks	Dec 28	Option Exercise	3.20	5,400	17,280	8,400	Dec 29 04:46 PM
Epstein David M.	See Remarks	Dec 15	Option Exercise	6.42	2,500	16,050	705,423	Dec 16 07:39 PM
Roberts Christopher D.	Chief Scientific Officer	Dec 15	Option Exercise	10.86	3,200	34,752	3,200	Dec 16 07:42 PM
Hatzis-Schoch Brent	See Remarks	Dec 14	Option Exercise	3.20	4,078	13,050	7,078	Dec 16 07:41 PM
Hatzis-Schoch Brent	See Remarks	Dec 14	Sale	34.95	4,078	142,522	3,000	Dec 16 07:41 PM
Leggett Thomas	Chief Financial Officer	Dec 08	Option Exercise	10.86	3,000	32,580	3,000	Dec 10 04:16 PM
Leggett Thomas	Chief Financial Officer	Dec 08	Sale	33.78	3,000	101,327	0	Dec 10 04:16 PM
Roberts Christopher D.	Chief Scientific Officer	Dec 03	Option Exercise	10.86	2,500	27,150	2,500	Dec 04 04:34 PM
Roberts Christopher D.	Chief Scientific Officer	Dec 03	Sale	32.42	2,500	81,055	0	Dec 04 04:34 PM
Epstein David M.	See Remarks	Dec 01	Option Exercise	6.42	3,000	19,260	714,923	Dec 03 04:17 PM
Epstein David M.	See Remarks	Dec 01	Sale	32.71	12,000	392,574	702,923	Dec 03 04:17 PM
Versant Venture Capital VI, L.	10% Owner	Nov 30	Sale	33.15	10,393	344,513	874,099	Dec 01 07:13 PM
Bolzon Bradley J PhD	Director	Nov 30	Sale	33.15	10,393	344,513	874,099	Dec 01 07:13 PM
Bolzon Bradley J PhD	Director	Nov 19	Sale	33.01	130,017	4,291,861	968,954	Nov 23 04:39 PM
Versant Venture Capital VI, L.	10% Owner	Nov 19	Sale	33.01	114,854	3,791,331	4,818,600	Nov 23 04:41 PM
Versant Venture Capital VI, L.	10% Owner	Nov 19	Sale	33.01	15,163	500,531	968,954	Nov 23 04:41 PM
Versant Venture Capital VI, L.	10% Owner	Nov 18	Sale	33.09	63	2,085	984,117	Nov 19 09:19 PM
Versant Venture Capital VI, L.	10% Owner	Nov 18	Sale	33.09	473	15,653	4,933,454	Nov 19 09:19 PM
Bolzon Bradley J PhD	Director	Nov 18	Sale	33.09	536	17,738	984,117	Nov 19 09:19 PM
Versant Venture Capital VI, L.	10% Owner	Nov 17	Sale	33.05	489	16,161	984,180	Nov 19 09:19 PM
Versant Venture Capital VI, L.	10% Owner	Nov 17	Sale	33.05	3,705	122,450	4,933,927	Nov 19 09:19 PM
Bolzon Bradley J PhD	Director	Nov 17	Sale	33.05	4,194	138,611	984,180	Nov 19 09:19 PM
Versant Venture Capital VI, L.	10% Owner	Nov 16	Sale	33.01	23	759	984,669	Nov 17 07:33 PM
Versant Venture Capital VI, L.	10% Owner	Nov 16	Sale	33.01	177	5,843	4,937,632	Nov 17 07:33 PM
Bolzon Bradley J PhD	Director	Nov 16	Sale	33.01	200	6,603	984,669	Nov 17 07:28 PM
Versant Venture Capital VI, L.	10% Owner	Nov 13	Sale	33.77	525	17,731	984,692	Nov 17 07:33 PM
Versant Venture Capital VI, L.	10% Owner	Nov 13	Sale	33.77	3,975	134,253	4,937,809	Nov 17 07:33 PM
Bolzon Bradley J PhD	Director	Nov 13	Sale	33.77	4,500	151,984	984,692	Nov 17 07:28 PM
Hatzis-Schoch Brent	See Remarks	Nov 12	Option Exercise	3.20	4,078	13,050	7,078	Nov 13 04:25 PM
Versant Venture Capital VI, L.	10% Owner	Nov 12	Sale	34.15	1,819	62,116	985,217	Nov 13 07:47 PM
Versant Venture Capital VI, L.	10% Owner	Nov 12	Sale	34.15	13,779	470,526	4,941,784	Nov 13 07:47 PM
Bolzon Bradley J PhD	Director	Nov 12	Sale	34.15	15,598	532,642	985,217	Nov 13 07:46 PM
Hatzis-Schoch Brent	See Remarks	Nov 12	Sale	33.99	4,078	138,607	3,000	Nov 13 04:25 PM
Roberts Christopher D.	Chief Scientific Officer	Nov 11	Option Exercise	10.86	5,000	54,300	5,000	Nov 13 04:26 PM
Versant Venture Capital VI, L.	10% Owner	Nov 11	Sale	34.73	1,471	51,091	987,036	Nov 12 05:41 PM
Versant Venture Capital VI, L.	10% Owner	Nov 11	Sale	34.73	11,146	387,127	5,646,377	Nov 12 05:41 PM
Bolzon Bradley J PhD	Director	Nov 11	Sale	34.73	12,617	438,217	987,036	Nov 12 05:38 PM
Roberts Christopher D.	Chief Scientific Officer	Nov 11	Sale	34.90	5,000	174,500	0	Nov 13 04:26 PM
Versant Venture Capital VI, L.	10% Owner	Nov 10	Sale	33.83	3,145	106,381	988,507	Nov 12 05:41 PM
Versant Venture Capital VI, L.	10% Owner	Nov 10	Sale	33.83	23,821	805,755	5,657,523	Nov 12 05:41 PM
Bolzon Bradley J PhD	Director	Nov 10	Sale	33.83	26,966	912,136	988,507	Nov 12 05:38 PM
Leggett Thomas	Chief Financial Officer	Nov 09	Option Exercise	10.86	3,000	32,580	3,000	Nov 12 05:00 PM
Bolzon Bradley J PhD	Director	Nov 09	Sale	33.06	6,300	208,250	991,652	Nov 10 07:24 PM
Versant Venture Capital VI, L.	10% Owner	Nov 09	Sale	33.06	735	24,296	991,652	Nov 10 07:24 PM
Versant Venture Capital VI, L.	10% Owner	Nov 09	Sale	33.06	5,565	183,954	5,681,344	Nov 10 07:24 PM
Leggett Thomas	Chief Financial Officer	Nov 09	Sale	32.96	3,000	98,892	0	Nov 12 05:00 PM
Bolzon Bradley J PhD	Director	Nov 06	Sale	33.13	3,100	102,698	992,387	Nov 10 07:24 PM
Versant Venture Capital VI, L.	10% Owner	Nov 06	Sale	33.13	362	11,993	992,387	Nov 10 07:24 PM
Versant Venture Capital VI, L.	10% Owner	Nov 06	Sale	33.13	2,738	90,706	5,686,909	Nov 10 07:24 PM
Bolzon Bradley J PhD	Director	Nov 05	Sale	33.15	8,848	293,287	992,749	Nov 06 04:49 PM
Versant Venture Capital VI, L.	10% Owner	Nov 05	Sale	33.15	1,032	34,208	992,749	Nov 06 04:44 PM
Versant Venture Capital VI, L.	10% Owner	Nov 05	Sale	33.15	7,816	259,079	5,689,647	Nov 06 04:44 PM
Bolzon Bradley J PhD	Director	Nov 04	Sale	33.14	2,500	82,839	993,781	Nov 06 04:49 PM
Versant Venture Capital VI, L.	10% Owner	Nov 04	Sale	33.14	292	9,676	993,781	Nov 06 04:44 PM
Versant Venture Capital VI, L.	10% Owner	Nov 04	Sale	33.14	2,208	73,164	5,697,463	Nov 06 04:44 PM
Roberts Christopher D.	Chief Scientific Officer	Nov 03	Option Exercise	10.86	2,500	27,150	2,500	Nov 04 08:37 PM
Roberts Christopher D.	Chief Scientific Officer	Nov 03	Sale	31.95	2,500	79,873	0	Nov 04 08:37 PM
Epstein David M.	See Remarks	Nov 02	Option Exercise	6.42	3,000	19,260	723,923	Nov 03 07:56 PM
Epstein David M.	See Remarks	Nov 02	Sale	31.14	12,000	373,656	711,923	Nov 03 07:56 PM
Versant Venture Capital VI, L.	10% Owner	Oct 27	Sale	33.03	93	3,072	994,073	Oct 28 05:58 PM
Versant Venture Capital VI, L.	10% Owner	Oct 27	Sale	33.03	707	23,354	5,699,671	Oct 28 05:58 PM
Bolzon Bradley J PhD	Director	Oct 27	Sale	33.03	800	26,426	994,073	Oct 28 05:51 PM
Versant Venture Capital VI, L.	10% Owner	Oct 26	Sale	33.30	945	31,473	994,166	Oct 28 05:58 PM
Versant Venture Capital VI, L.	10% Owner	Oct 26	Sale	33.30	7,158	238,394	5,700,378	Oct 28 05:58 PM
Bolzon Bradley J PhD	Director	Oct 26	Sale	33.30	8,103	269,867	994,166	Oct 28 05:51 PM
Versant Venture Capital VI, L.	10% Owner	Oct 19	Sale	33.43	494	16,515	995,111	Oct 20 08:09 PM
Versant Venture Capital VI, L.	10% Owner	Oct 19	Sale	33.43	3,739	124,998	5,707,536	Oct 20 08:09 PM
Bolzon Bradley J PhD	Director	Oct 19	Sale	33.43	4,233	141,513	995,111	Oct 20 08:03 PM
Versant Venture Capital VI, L.	10% Owner	Oct 16	Sale	33.57	1,016	34,110	995,605	Oct 20 08:09 PM
Versant Venture Capital VI, L.	10% Owner	Oct 16	Sale	33.57	7,697	258,410	5,711,275	Oct 20 08:09 PM
Bolzon Bradley J PhD	Director	Oct 16	Sale	33.57	8,713	292,520	995,605	Oct 20 08:03 PM
Versant Venture Capital VI, L.	10% Owner	Oct 15	Sale	33.03	327	10,802	996,621	Oct 20 08:09 PM
Versant Venture Capital VI, L.	10% Owner	Oct 15	Sale	33.03	2,473	81,694	5,718,972	Oct 20 08:09 PM
Bolzon Bradley J PhD	Director	Oct 15	Sale	33.03	2,800	92,496	996,621	Oct 20 08:03 PM
Bolzon Bradley J PhD	Director	Oct 14	Sale	33.09	5,501	182,031	996,948	Oct 15 07:26 PM
Versant Venture Capital VI, L.	10% Owner	Oct 14	Sale	33.09	642	21,244	996,948	Oct 15 07:22 PM
Versant Venture Capital VI, L.	10% Owner	Oct 14	Sale	33.09	4,859	160,787	5,721,445	Oct 15 07:22 PM
Bolzon Bradley J PhD	Director	Oct 13	Sale	33.39	11,739	391,984	997,590	Oct 15 07:26 PM
Versant Venture Capital VI, L.	10% Owner	Oct 13	Sale	33.39	1,369	45,713	997,590	Oct 15 07:22 PM
Versant Venture Capital VI, L.	10% Owner	Oct 13	Sale	33.39	10,370	346,271	5,726,304	Oct 15 07:22 PM
Hatzis-Schoch Brent	See Remarks	Oct 12	Option Exercise	3.20	4,078	13,050	7,078	Oct 14 04:32 PM
Hatzis-Schoch Brent	See Remarks	Oct 12	Sale	32.70	4,078	133,331	3,000	Oct 14 04:32 PM
Bolzon Bradley J PhD	Director	Oct 12	Sale	33.11	400	13,243	998,959	Oct 13 07:48 PM
Versant Venture Capital VI, L.	10% Owner	Oct 12	Sale	33.11	47	1,556	998,959	Oct 13 07:41 PM
Versant Venture Capital VI, L.	10% Owner	Oct 12	Sale	33.11	353	11,687	5,736,674	Oct 13 07:41 PM
Bolzon Bradley J PhD	Director	Oct 09	Sale	33.67	3,800	127,933	999,006	Oct 13 07:48 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience